AVANIR Pharmaceuticals to Present April 3 at the American Stock Exchange Online Conference

SAN DIEGO, Apr 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- AVANIR Pharmaceuticals (Amex: AVN) today announced that it will be presenting at the American Stock Exchange's upcoming online conference, "Where Savvy Investors Meet Undiscovered Companies." Management's slide presentation will be webcast live during the conference on Wednesday, April 3, 2002 at 3:00 p.m. Eastern / 12:00 p.m. Pacific.

The webcast will feature President and Chief Executive Officer Gerald J. Yakatan, Ph.D. To listen to the live webcast, please visit the Company's web site at www.avanir.com , or go to www.amex.com or www.ccbn.com . For those unable to participate during the live webcast, AVANIR's presentation will be archived on these sites for 90 days.

AVANIR Pharmaceuticals, based in San Diego, is a diversified biopharmaceutical company with an FDA-approved product. AVANIR is engaged in research, development, commercialization, licensing and sales of innovative drug products and antibody generation services.

AVANIR press releases and presentations, including any forward-looking statements contained therein, should be reviewed in conjunction with the company's Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "intend," "plan" or "expect." Research findings are not always supportable by evidence obtained from subsequent clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

For further information, please contact: General Information, Kristen McNally, +1-310-407-6548, kmcnally@webershandwick.com, or Analyst/Investor, Tricia Ross, +1-310-407-6540, tross@webershandwick.com, or Media, Al Orendorff, +1-312-640-6775, aorendorff@webershandwick.com, all of FRB Weber Shandwick, for AVANIR Pharmaceuticals; or Investor Relations, Patrice Saxon of AVANIR Pharmaceuticals, +1-858-622-5202, psaxon@avanir.com

SOURCE AVANIR Pharmaceuticals

CONTACT:
General Information, Kristen McNally,
+1-310-407-6548, kmcnally@webershandwick.com,
or Analyst/Investor, Tricia Ross,
+1-310-407-6540, tross@webershandwick.com,
or Media, Al Orendorff,
+1-312-640-6775, aorendorff@webershandwick.com,
all of FRB Weber Shandwick, for AVANIR Pharmaceuticals;
or Investor Relations,
Patrice Saxon of AVANIR Pharmaceuticals, +1-858-622-5202, psaxon@avanir.com

URL: http://www.avanir.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.